BioSpace News Archive

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer, Dr. Lawrence Weiss, Chief Medical Officer, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the virtual 39 th Annual J.P. Morgan Healthcare Conference 2

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021. The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Comp

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will provide a corporate update at the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021. The presentation will be available on-demand thr

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, announced a new near-term business target.

CIMC Enric Holdings Limited, announced that its subsidiary Zhangjiagang CIMC Sanctum Cryogenic Equipment Co., Ltd recently started R&D of liquid nitrogen biological containers for long-term cryogenic storage of vaccines, stem cells, plasma, semen, embryos and various tissues and organs for the needs of the biomedical industry.

Program addressing rare mineralization disorders expected to enroll first subject in H1’21 and provide preliminary safety and biomarker data in H2’21

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), today announced that the Company has received allowance of the Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for the Phase 2 clinical study of its vaccine candidate ARCT-021 following review of data from the Phase 1/2 study.

HDF Assist Device Complete; Special 510(k) to be Filed in Early 2021 Nephros Granted Patent Covering Technology in HDF Assist Module Nephros Expands EndoPur® and S100 Filter Labels to Include Heat Disinfection

Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that completion of enrollment of 350 subjects in the controlled clinical study K031 evaluating Microbiome Metabolic Therapy (MMT™) candidate KB109 in the treatment of mild-to-moderate COVID-19.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommends that BridgeBio stockholders and Eidos Therapeutics, Inc. (Nasdaq: EIDX) stockholders vote “FOR” BridgeBio’s proposed merger with Eidos and each of the other proposals to be considered at both companies’ virtual special meetings to be held on January 19, 2021.